BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

...L858R substitution in NSCLC patients for treatment with AZ’s Iressa gefitinib or Tagrisso osimertinib, or Tarceva erlotinib...
BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

...Eli Lilly and Co. (NYSE:LLY) said FDA approved an sNDA for Cyramza ramucirumab plus Tarceva erlotinib...
...with EGFR exon 19 deletions or exon 21 mutations. Cyramza is a VEGFR-2 antagonist and Tarceva...
BioCentury | Feb 27, 2020
Product Development

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

...Lilly and Co. (NYSE:LLY) has a favorable risk-benefit profile when used in combination with Tarceva erlotinib...
...2 Elizabeth S. Eaton and Hongjiang Li, Staff Writers Cyramza, ramucirumab (IMC-1121B, LY3009806) Tarceva, erlotinib (R1415, RG115, CP-358,774, OSI-774) AB122 bempedoic...
BioCentury | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

...and II testing for various solid tumors; and marketed small molecule EGFR inhibitors include Tarceva erlotinib...
BioCentury | Oct 31, 2019

Allosteric inhibitor of PGAM1 identified for NSCLC

...benzenesulfonamide-based allosteric inhibitor of PGAM1, given alone or in combination with the EGFR inhibitor Tarceva erlotinib...
...an allosteric site. The PGAM1 inhibitor sensitized two Tarceva-resistant xenograft mouse models of NSCLC to Tarceva...
...Jiao Tong University School of Medicine, Shanghai, China email: yshen0510@sjtu.edu.cn Claire Quang Tarceva, erlotinib (R1415, RG115, CP-358,774, OSI-774) Shanghai...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...with first-generation EGFR inhibitor Iressa gefitinib from AstraZeneca. Novartis is testing capmatinib with Roche’s Tarceva erlotinib...
BioCentury | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

...CDK4 and PI3K that promotes cell growth and survival. A combination of EGFR inhibitor Tarceva erlotinib...
...alone. In xenograft mouse models of lung and pancreatic cancer, the KRAS G12C inhibitor plus Tarceva...
...Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd. and the Genentech Inc. unit of Roche market Tarceva...
BioCentury | Aug 9, 2019
Clinical News

AZ notches another win in cancer with Tagrisso in NSCLC

...in July 2017, enrolled 556 patients who received Tagrisso or competing oral EGFR inhibitors Tarceva erlotinib...
BioCentury | Apr 22, 2019
Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

...of dual-mutant PDAC, two shRNA against RAF1 plus the EGFR inhibitors Iressa gefitinib or Tarceva erlotinib...
...Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd. and the Genentech Inc. unit of Roche market Tarceva...
BioCentury | Mar 15, 2019
Clinical News

Lilly looks to expand Cyramza's label into first-line NSCLC

...with Tarceva erlotinib met the primary endpoint of improving progression-free survival (PFS) vs. placebo plus Tarceva...
...with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 substitution mutations. Tarceva...
...have EGFR exon 19 deletions or exon 21 substitution mutations. According to its U.S. label, Tarceva...
Items per page:
1 - 10 of 889